KR20220103707A - Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 - Google Patents
Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR20220103707A KR20220103707A KR1020227014562A KR20227014562A KR20220103707A KR 20220103707 A KR20220103707 A KR 20220103707A KR 1020227014562 A KR1020227014562 A KR 1020227014562A KR 20227014562 A KR20227014562 A KR 20227014562A KR 20220103707 A KR20220103707 A KR 20220103707A
- Authority
- KR
- South Korea
- Prior art keywords
- gaba
- disorder
- receptor
- compound
- less
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962907763P | 2019-09-30 | 2019-09-30 | |
US62/907,763 | 2019-09-30 | ||
PCT/US2020/052167 WO2021067089A1 (en) | 2019-09-30 | 2020-09-23 | Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220103707A true KR20220103707A (ko) | 2022-07-22 |
Family
ID=75338529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020227014562A KR20220103707A (ko) | 2019-09-30 | 2020-09-23 | Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4135710A4 (zh) |
JP (1) | JP2022552788A (zh) |
KR (1) | KR20220103707A (zh) |
CN (1) | CN115087450A (zh) |
BR (1) | BR112022006085A2 (zh) |
CA (1) | CA3159087A1 (zh) |
IL (1) | IL291835A (zh) |
MX (1) | MX2022003823A (zh) |
WO (1) | WO2021067089A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021252314A1 (en) * | 2020-06-08 | 2021-12-16 | Eliem Therapeutics, Inc. | Methods of treating female health conditions related to sex hormones |
WO2024020953A1 (zh) * | 2022-07-28 | 2024-02-01 | 湖南科益新生物医药有限公司 | 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
HUE041369T2 (hu) * | 2013-04-17 | 2019-05-28 | Sage Therapeutics Inc | 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására |
NZ769008A (en) * | 2014-10-16 | 2024-03-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
AU2017342521A1 (en) * | 2016-10-14 | 2019-04-18 | Marinus Pharmaceuticals, Inc | Method of administering a neurosteroid to effect electroencephalographic (EEG) burst suppression |
WO2020210116A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
-
2020
- 2020-09-23 CN CN202080082811.4A patent/CN115087450A/zh active Pending
- 2020-09-23 BR BR112022006085A patent/BR112022006085A2/pt unknown
- 2020-09-23 MX MX2022003823A patent/MX2022003823A/es unknown
- 2020-09-23 CA CA3159087A patent/CA3159087A1/en active Pending
- 2020-09-23 WO PCT/US2020/052167 patent/WO2021067089A1/en unknown
- 2020-09-23 EP EP20872608.3A patent/EP4135710A4/en active Pending
- 2020-09-23 JP JP2022519997A patent/JP2022552788A/ja active Pending
- 2020-09-23 IL IL291835A patent/IL291835A/en unknown
- 2020-09-23 KR KR1020227014562A patent/KR20220103707A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
MX2022003823A (es) | 2022-08-17 |
EP4135710A4 (en) | 2023-12-06 |
EP4135710A1 (en) | 2023-02-22 |
WO2021067089A1 (en) | 2021-04-08 |
BR112022006085A2 (pt) | 2023-03-14 |
CA3159087A1 (en) | 2021-04-08 |
IL291835A (en) | 2022-06-01 |
JP2022552788A (ja) | 2022-12-20 |
CN115087450A (zh) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3873883B1 (en) | Method of synthesis | |
US11571432B2 (en) | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof | |
EP2260022B1 (de) | Substituierte cyclohexyldiamine | |
BR112020020008A2 (pt) | Sais mono ácido de 6-aminoisoquinolinas e seus usos | |
KR20220103707A (ko) | Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 | |
KR20200110648A (ko) | 비라세믹 혼합물 및 이의 용도 | |
BR122014023207A2 (pt) | Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos | |
AU2019282231A1 (en) | EAAT2 activators and methods of using thereof | |
CA2905570A1 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
JP6831376B2 (ja) | トリアゾール誘導体 | |
US11958821B2 (en) | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | |
BR112015000012B1 (pt) | Composto e uso do composto | |
CN115515682A (zh) | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
US20240238313A1 (en) | Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders | |
US20220296613A1 (en) | Food-independent dosing of cv-10155 to treat gabaa disorders | |
CA3232914A1 (en) | Lsd derivatives, synthesis & method for treatment of diseases and disorders | |
WO2023130117A1 (en) | Deuterated organic compounds and uses thereof | |
EP4199723A1 (en) | Methods of treating fibromyalgia with neuroactive steroids | |
CN118284607A (zh) | 用于治疗疾病和障碍的lsd衍生物、合成和方法 | |
WO2023130119A1 (en) | Deuterated organic compounds and uses thereof | |
TW202116760A (zh) | 四員環類衍生物調節劑、其製備方法和應用 | |
US20220048939A1 (en) | Aromatic ring compound | |
JP2014532708A (ja) | ニコチン性受容体非競合的モジュレーター |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination |